Calls for price cuts on cancer meds

If the government says cancer drugs aren't worth the cost, then what? Ask drugmakers to cut their prices. After the U.K.'s National Institute for Health and Clinical Excellence rejected four kidney-cancer treatments yesterday, advocates immediately ramped up pressure on pharmaceutical companies to lower their price tags. Report

Suggested Articles

Olumiant
Marketing

Eli Lilly, Incyte's Olumiant notches atopic dermatitis trial win

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

by Kyle Blankenship
Manufacturing

Krystal Biotech investing $10M on facility for gene therapies

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

by Eric Palmer
AbbVie
Pharma Asia

AbbVie donates $1M-plus of HIV drug for deadly coronavirus

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.

by Angus Liu